Kornimate/medical-research-clean huggingface dataset:
web-based survey of pain, stress and complementary and alternative medicine

Conditions: Gastrointestinal Diseases; Chronic Pain; Stress; Anxiety; Depression

Summary: the investigators are inviting people with fibromyalgia, ibs, interstitial cystitis, chronic pain, and other chronic and recurring conditions to sign up and participate in a year-long internet-based survey to study the effectiveness of alternative medicine and the interactions among stress and coping, pain, and treatment outcomes. the survey is called procaim, which stands for patient-reported outcomes from complementary, alternative, and integrative medicine. procaim was developed under a grant to ucla researchers from the national center for complementary and alternative medicine. this is a web-based study composed of surveys that will recur at intervals over 1 year! to enroll * log in to our web site: http://www.procaim.org/ * register as a new user. * select clinic name: clinicaltrials.gov. * read and sign the consent form. after participants"sign" the form with their email address, participants can begin to answer the first in a series of questionnaires. the system will send participants email reminders at the time of each scheduled follow-up for one year. for further information about procaim, please contact: * deborah ackerman, ph.d. * department of epidemiology * ucla school of public health * box 951772 * los angeles, ca 90095-1772 * deborah.ackerman@ucla.edu

procaim, which stands for patient-reported outcomes from complementary, alternative, and integrative medicine, was developed to collect and manage longitudinal patient data and implement patient-based outcomes assessment protocols at clinical sites around the country that offer various forms of cam as well as clinics that provide the combination of conventional medicine with complementary and alternative therapies. procaim is currently being used for a 12 month longitudinal survey to evaluate interactions among stress, symptoms, severity, and general well-being among people with fibromyalgia, ibs, chronic fatigue, and other chronic pain conditions, and the frequency and impact of co-morbid conditions among users of complementary and alternative medicines.

Eligibility criteria:
inclusion criteria: * everyone who has a computer and is fluent in english will be eligible. exclusion criteria: * only people with access to personal computers and the internet and fluency in english will be able to participate. these exclusions are not based on age, gender, pregnancy, racial, or ethnic origin.

Keywords: fibromyalgia irritable bowel syndrome interstitial cystitis chronic fatigue syndrome vulvodynia chronic stress chronic pain stress-related conditions functional gi disorders
evaluation of nexfin during cesarean delivery to detect hypotension

Conditions: Hypotension

Summary: hypotension after spinal anesthesia for cesarean delivery occurs frequently. oscillometric measurement gives intermittent informations. nexfin, a continuous noninvasive device, could help to detect hypotension.


Eligibility criteria:
inclusion criteria: * adult patients undergoing elective cesarean delivery performed under spinal anesthesia exclusion criteria: * patients with a heart rhythm disorder, raynaud's disease or a history of vascular surgery of the upper limb

Keywords: hypotension cesarean delivery
a multicenter prospective registry for the management of degenerative spine disorders

Conditions: Degenerative Diseases, Spinal Cord

Summary: details regarding the degenerative spine disorders will be collected with a specific focus on the use of osteobiologics in treating degenerative conditions and their impact on fusion, as well as patient-reported outcomes for these conditions.

the registry is designed to be open-ended. however, a statistical evaluation of the content und structure of database and crfs in order to investigate the feasibility and quality of data collection is planned to take place prior to the registry expansion. variables applicable to patients with a degenerative spine disorder which will be collected in the registry include: * patient details * symptoms * diagnosis * imaging assessment * treatment details feasibility phase: the statistical evaluation of the feasibility and quality of data collection will be performed after the first 5 sites have each enrolled 12 patients with a degenerative pathology and documented one follow-up visit. during this evaluation, enrolment of further patients can be continued. based on the findings of this feasibility phase, adjustments to the existing database can be performed before the registry is rolled out on larger scale. registry expansion: following the evaluation process of the feasibility phase, the registry will be expanded to allow data entry in more sites globally. multi-site participation of this registry will be rolled-out in stages, and will be offered to sites with appropriate expertise which are selected based on their potential (interest, resources and expected patient volume).

Eligibility criteria:
inclusion criteria: * patient aged 18 years or older * patient diagnosed with a degenerative spine disorder who receives treatment for the degenerative spine disorder * patient capable of understanding the content of the patient information / informed consent form * patient willing and able to participate in the registry * patient who has agreed to participate in the registry by providing consent according to the applicable local law and the declaration of helsinki exclusion criteria: * none

Keywords: registry spine osteobiologics spinal fusion
national evaluation of the adherence to recommendations of venous thrombo embolism treatment in cancer patients

Conditions: Neoplasms; Venous Thromboembolism

Summary: treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of lmwh (low molecular weight heparin) instead of vka (vitamin k antagonist) treatment during 6 months. international recommendations have diffused this option.it is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of lmwh.


Eligibility criteria:
inclusion criteria: all patients with cancer present in the clinic, hospital, out patients diagnosed with a vte during the 6 previous months. vte can be symptomatic or asymptomatic, can be located close to a central line, and of any type (dvt, pe, svt) exclusion criteria: * patient already included in a trial studying antithrombotic therapy * patient refusing the study * patient under 18 and/or not competent to give informed consent

Keywords: pe dvt svt lmwh vka international venous thromboembolism recommendations
comparison of celecoxib 200 mg bid, loxoprofen sodium 60 mg tid and placebo in low back pain in japan

Conditions: Low Back Pain

Summary: to verify the superiority of celecoxib (ym177) 200 mg bid to placebo in treatment of patients with low back pain as well as non-inferiority to loxoprofen sodium 60 mg tid.


Eligibility criteria:
inclusion criteria: * patients who have the major site of the low back pain at the 12th thoracic vertebra or lower * patients who have had low back pain for at least two weeks exclusion criteria: * patients who have a previous history or complication of rheumatoid arthritis, spondylarthrosis with negative serum reaction (ankylosing spondylarthritis, psoriatic arthritis), metastasis of tumor, paget's disease, fibromyalgia, tumor or infection of spinal cord or intervertebral disc, or any other disease which can cause systemic pain
intravascular volume expansion to neuroendocrine-renal function profiles in chronic heart failure

Conditions: Heart Failure

Summary: researchers are trying learn more about how the heart and blood volume interact in subjects with heart failure and how measuring blood volume may help them develop better ways of treating and managing heart failure patients.


Eligibility criteria:
inclusion criteria: * acute decompensated chronic heart failure, diagnosed clinically with volume overload by the primary heart failure provider or emergency department physician and admitted to hospital. * new york hear association functional class iii-iva with stage c or d heart failure with left ventricular ejection fraction \<50% * intended treatment plan with intravenous loop diuretic therapy during hospitalization * meeting none of the exclusion criteria exclusion criteria: * age \< 18 years * having received any investigational drug or device within 30 days prior to entry into the study. * clinically unstable patients (e.g. systolic blood pressure \< 90 mmhg, ongoing requirement for vasopressors or mechanical circulatory support, or mechanical ventilation). * hospitalization within three months prior to study for hemodialysis or an ongoing requirement for hemodialysis or ultrafiltration. * prior organ transplantation or being on a waiting list for organ transplantation * presence of cardiac conditions such as clinically significant cardiac valve stenosis, hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or primary arterial pulmonary hypertension (group 1 pah). * history of blood pressure \> 190/115 mmhg or unexplained syncope within the past 3 months. * symptomatic carotid artery disease, known critical carotid stenosis, or stroke within the past 3 months * clinically significant intrinsic renal disease (egfr \<15 ml/min/1.72m2), renal artery stenosis, or history of fibromuscular dysplasia of the renal arteries * baseline hemoglobin \< 8.5 g/dl, aspartate aminotransferase (ast) or alanine aminotransferase (alt) that is five times or more the upper limit of normal or bilirubin three times or more the upper limit of normal * history of alcohol abuse within the past 6 months.
the development of pancreatic injury in the course of severe acute respiratory syndrome coronavirus 2 infection

Conditions: Pancreatitis

Summary: although covid-19 disease due to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common. in this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury in the course of covid 19 disease.


Eligibility criteria:
inclusion criteria: * patients with amylase and lipase levels measured during covid-19 disease with or without pneumonia exclusion criteria: * patients with pregnancy * patients whose amylase and lipase levels were not measured during covid 19 disease * patients with known solid organ malignacy * patients with known hematologic malignacy
hidrawear study for hidradenitis suppurativa wounds

Conditions: Hidradenitis Suppurativa; Hidradenitis

Summary: the product, hidrawear ax (www.hidrawear.com) is and adhesive free wound dressing system for the every day home care of hidradenitis suppurativa (hs), a debilitating disease of the skin for which there are limited wound dressing products. this is a study to assess the use hidrawear ax vs current product and method of use, and to determine the impact on patients' quality of life.

the objective is to evaluate the ease of use of hidrawear ax compared to the subject's existing product use in 23 subjects with hs (hidradenitis suppurativa). secondary objectives are to evaluate if hidrawear ax: * is comfortable * improves quality of life * faster to use than the subject's existing product * reduces dressing related pain * secure dressing retention this pilot study will evaluate usability - the safety, efficacy and performance of hidrawear ax in the home setting. quality of life, ease of use and comfort of hidrawear ax will be assessed. the clinical effect of the wound pad will not be assessed.

Eligibility criteria:
inclusion criteria: * in order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. provision of signed and dated informed consent form in english. 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. female, aged \>18 4. diagnosed with hidradenitis suppurativa 5. hidradenitis suppurativa affecting the axilla 6. exuding lesion that requires wound dressings exclusion criteria: * 1. recent surgery \<3 months in axilla 2. psoriasis, dermatitis or skin conditions/rash other than hidradenitis suppurativa on or near affected area 3. pregnancy or lactation 4. known allergic reactions to components of hidrawear ax
immunogenicity and safety study of a rapid immunization schedule with fsme-immun 0.5 ml in healthy adults aged 16 - 65 years

Conditions: Encephalitis, Tick-borne

Summary: the objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with fsme-immun 0.5 ml using a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.


Eligibility criteria:
inclusion criteria: * understanding the nature of the study, agreement to its provisions and written informed consent * written informed consent of subject´s parents / legal guardians (if subject is under 18 years of age) * aged \>= 16 years (from the 16th birthday) to \<= 65 years (to the last day before the 66th birthday) * clinically healthy, (i. e. the physician would have no reservations vaccinating with fsme-immun 0.5 ml outside the scope of a clinical trial) * negative pregnancy test result at the first medical examination (if female and capable of bearing children) * agreeing to employ adequate birth control measures for the duration of the study (if female and capable of bearing children) * agreeing to keep a subject diary. exclusion criteria: * history of any previous tbe vaccination * history of tbe infection * history of infection with other flaviviruses * history of vaccination against yellow fever and/or japanese b-encephalitis * history of allergic reactions, in particular to one of the components of the vaccine * suffering from a disease (e.g. autoimmune disease) or undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions * known or suspected problem with drug or alcohol abuse (\> 4 liters wine / week or equivalent level of other alcoholic beverages) * donation of blood or plasma within one month of study start * having received a blood transfusion or immunoglobulins within one month of study entry * hiv positivity (an hiv test is not required specifically for the purpose of this study * simultaneous participation in another clinical trial including administration of an investigational product * participating in any other clinical study within six weeks prior to study start * participated in another baxter vaccine study within the last six months (with the exception of follow-up studies) * pregnancy or lactation (if female) * having received any other vaccination within two weeks prior to study entry

Keywords: tick-borne encephalitis
evaluate the safety and efficacy of cll1+cd33 car-t in patients with r/r aml

Conditions: AML

Summary: this is an open label, phase i study to assess the safety and efficacy of cll1+cd33 car-t in patients with relapsed and refractory acute myeloid leukemia


Eligibility criteria:
inclusion criteria: 1. all subjects must sign and date the informed consent before initiating any study specific procedures or activities; 2. diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (aml); 3. the expression of cll1 and cd33 in aml blast is positive ; 4. the patient has recovered from the toxicity of previous treatment; 5. ecog score ≤ 2 and expected survival period is not less than 3 months; 6. adequate organ function defined as: ast ≤3×uln; alt ≤3×uln; total bilirubin ≤1.5×uln; serum creatinine ≤1.5×uln, or ccr≥60 ml/min; hemoglobin ≥60g/l ; indoor oxygen saturation ≥92%; lvef≥45%; 7. pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test; 8. from the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception exclusion criteria: 1. diagnosis of acute promyelocytic leukemia; 2. history or presence of a cns disorder; 3. hbsag or hbcab are positive; hcv 、hiv and syphilis antibody are positive, cmv dna in peripheral blood is more than≥500 copies /ml; 4. history of severe hypersensitivity reaction; 5. history of myocardial infarction, cardiac angioplasty or stenting, unstable angina, new york heart association class ii or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment; 6. history of organ transplant surgery; 7. required systemic application of immunosuppressive or other drugs; 8. auto-sct within the 3 months before enrollment; 9. active autoimmune or inflammatory diseases of the nervous system (e.g., guillain-barre syndrome (gbs), amyotrophic lateral sclerosis (als)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (pres)); 10. requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (tls)) ; 11. presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management; 12. live vaccine received within the ≤ 4 weeks before enrollment; 13. persons with serious mental illness; 14. history of major surgical operations four weeks before enrollment; 15. history of alcoholism or substance abuse; 16. was identified by the investigators as unsuitable to participate in the study.
study to investigate the mass balance, metabolism, and excretion of [14c]pf-07321332 in healthy male participants.

Conditions: Healthy Participants

Summary: this study is to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of radiolabeled \[14c\]pf-07321332 in healthy male participants following oral administration with ritonavir.


Eligibility criteria:
inclusion criteria: * participants who are overtly healthy as determined by medical evaluation including medical history, physical examination (pe), laboratory tests, vital signs and standard 12 lead ecgs. * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). * participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures exclusion criteria: * positive test result for sars-cov-2 infection at the time of screening or day -1. * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * clinically relevant abnormalities requiring treatment (eg, acute myocardial infarction, unstable ischemic conditions, evidence of ventricular dysfunction, serious tachy or brady arrhythmias) or indicating serious underlying heart disease (eg, prolonged pr interval, cardiomyopathy, heart failure greater than new york heart association (nyha) 1, underlying structural heart disease, wolff parkinson-white syndrome). * any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy). * history of human immunodeficiency virus (hiv) infection, hepatitis b, or hepatitis c; positive testing for hiv, hepatitis b surface antigen (hbsag), or hepatitis b surface antibody (hcvab). hepatitis b vaccination is allowed. * use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention. * participant who have received a covid-19 vaccine within 7 days before screening or admission, or who are to be vaccinated with a covid-19 vaccine at any time during the study confinement period. * a positive urine drug test. * participants enrolled in a previous radio-nucleotide study or who have received radiotherapy within 12 months prior to screening or such that total radioactivity would exceed acceptable dosimetry (ie, occupational exposure of 5 rems per year).

Keywords: mass balance metabolism and execration covid-19 (coronavirus disease 2019) sars-cov-2 (severe acute respiratory syndrome coronavirus 2)
ultrasound assisted peripheral venous access in young children

Conditions: Catheterization, Peripheral

Summary: the purpose of this study is to learn how the use of ultrasound helps with the placement of an intravenous (i.v.) catheter in young children.

in an academic pediatric emergency depratment (ed), we performed a randomized clinical trial of children \< 7 years of age, who required i.v. access and who had failed the first i.v. attempt. we randomized patients to either continued standard i.v. attempts or ultrasound-assisted attempts. clinicians involved in the study received one hour of training in ultrasound localization of peripheral veins. in the ultrasound group, vein localization was performed by an ed physician who marked the skin overlying the target vessel. intravenous cannulation attempts were then immediately performed by a pediatric ed nurse who relied on the skin mark for vessel location. we allowed for technique cross-over after two failed i.v. attempts. we recorded success rate and location of access attempts.

Eligibility criteria:
inclusion criteria: * less than 7 years of age * emergency department patients * parents available for consent exclusion criteria: * critical illness

Keywords: pediatrics venous access emergency
efficacy study of vx001 vaccine in nsclc patients

Conditions: Non-small Cell Lung Cancer Metastatic

Summary: patients with stage iv or recurrent stage i-iii nsclc with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only hla-a\*0201 positive patients with tert expressing tumors will be included. the objective of the trial is survival rate at 12 months.


Eligibility criteria:
main inclusion criteria: 1. male or female ≥18 years of age; 2. documented stage iv nsclc as defined by iaslc lung cancer staging project (7th edition) or recurrent stage i-iii disease at least 6 months after resection or after the end of adjuvant chemotherapy or after standard locoregional treatment as defined by the american college of chest physicians; 3. patients treated with 4 cycles platinum based 1st line chemotherapy as defined by the american college of chest physicians (i.e. radiotherapy are not allowed except palliative radiotherapy of bone metastasis); 4. documented hla-a\*0201 positivity, as determined by a local laboratory; 5. tert-positive nsclc, as assessed by a central laboratory; for this, availability of adequate tissue biopsy from the primary tumor, lymph nodes or distant metastases is a prerequisite; 6. cr, pr, or sd according to recist 1.1 criteria after the completion of platinum-based first-line chemotherapy; 7. ecog performance status 0, 1; main exclusion criteria: 1. mixed small cell and nsclc histologies; 2. patients with stage iv or recurrent nsclc who have been previously treated with therapy other than platinum-based first-line chemotherapy; 3. prior treatment with cancer vaccines; 4. prior treatment with immunotherapy (e.g., interferons, interleukins, tnf, or biological response modifiers, such as gm-csf etc) within four weeks prior to randomization; 5. prior treatment with hormone (including corticosteroids) within 2 weeks prior to randomization; 6. prior treatment with any investigational drugs, within 4 weeks prior to randomization; 7. patients with brain metastases;

Keywords: nsclc vaccine